参考文献
［1］ Khan SS，Ning H，Shah SJ，et al.10-year risk equations for incident heart failure in the general population［J］.J Am Coll Cardiol，2019，73：2388-2397.
［2］ Gerber Y，Weston SA，Enriquez-Sarano M，et al.Atherosclerotic burden and heart failure after myocardial infarction［J］.JAMA Cardiol，2016，1：156-162.
［3］ Echouffo-Tcheugui JB，Erqou S，Butler J，et al.Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure：a systematic overview and meta-analysis［J］.JACC Heart Fail，2016，4：237-248.
［4］ Chamberlain AM，Boyd CM，Manemann SM，et al.Risk factors for heart failurein the community：Differences by age and ejection fraction［J］.Am J Med，2020，133：e237-e248.
［5］ Roger VL.Epidemiology of heart failure：A contemporary perspective［J］.Circ Res，2021，14（128）：1421-1434.
［6］ Mishra S，Kass DA.Cellular and molecular pathobiology of heart failure with preserved ejection fraction［J］.Nat Rev Cardiol，2021，18：400-423.
［7］ Tanai E，Frantz S.Pathophysiology of heart failure［J］.Compr Physiol，2015，6：187-214.
［8］ González A，Schelbert EB，Díez J，et al.Myocardial interstitial fibrosis in heart failure：Biological and translational perspectives［J］.J Am Coll Cardiol，2018，71：1696-1706.(https://www.daowen.com)
［9］ Hartupee J，Mann DL.Neurohormonal activation in heart failure with reduced ejection fraction［J］.Nat Rev Cardiol，2017，14：30-38.
［10］ Grosman-Rimon L，Billia F，Wright E，et al.Neurohormones，inflammatory mediators，and cardiovascular injury in the setting of heart failure［J］.Heart Fail Rev，2020，25：685-701.
［11］ Vergaro G，Aimo A，Prontera C，et al.Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved，mid-range and reduced ejection fraction［J］.Int J Cardiol，2019，296：91-97.
［12］ Pugliese NR，Masi S，Taddei S.The renin-angiotensin-aldosterone system：A crossroad from arterial hypertension to heart failure［J］.Heart Fail Rev，2020，25（1）：31-42.
［13］ Shiraishi Y，Kawana M，Nakata J，et al.Time-sensitive approach in the management of acute heart failure［J］.ESC Heart Fail，2021，8：204-221.
［14］ Triposkiadis F，Xanthopoulos A，Parissis J，et al.Pathogenesis of chronic heart failure：Cardiovascular aging，risk factors，comorbidities，and disease modifiers［J］.Heart Fail Rev，2022，27：337-344.
［15］ Sugumar H，Nanayakkara S，Prabhu S，et al.Pathophysiology of atrial fibrillation and heart failure：Dangerous interactions［J］.Cardiol Clin，2019，37：131-138.
［16］ Mazurek JA，Jessup M.Understanding heart failure［J］.Heart Fail Clin，2017，13：1-19.